The purpose of this study is to determine whether simvastatin treatment started within the first 12 hours from stroke onset improves neurological and functional outcomes, evaluated at seventh day/discharge or at the third month. Also, to demonstrate that simvastatin is safe and not associated with higher rates of hemorrhagic transformation in patients who receive thrombolysis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
104
Simvastatin 40 mgrs daily for three months.
Hospital General de Vic
Vic, Barcelona, Spain
Hospital Universitario de Albacete
Albacete, Spain
The primary outcome of this study is to determine whether simvastatin treatment started within the first 12 hours from stroke onset improves neurological and functional outcomes, evaluated at seventh day/discharge or at the third month.
Time frame: Seventh day (or discharge) and third month
The secondary outcome of this study is to demonstrate that simvastatin is safe and not associated with higher rates of hemorrhagic transformation in patients who receive thrombolysis.
Time frame: 24 to 78 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hospital de Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario de Bellvitge
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital de Basurto
Bilbao, Spain
Hospital General Yagüe
Burgos, Spain
Hospital de Ciudad Real
Ciudad Real, Spain
Hospital de Donostia
Donostia / San Sebastian, Spain
Hospital de León
León, Spain
...and 10 more locations